Генеральный директор Lakewood-Amedex представит стратегию разработки новых антибиотиков на конференции в Нью-Йорке

News provided by Lakewood-Amedex Biotherapeutics Inc. Sep 08, 2026, 08:02 ET SARASOTA, Fla., Sept. 8, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin ®  class, today announced that Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City. Details of the presentation are as follows: Event: | H.C. Wainwright 28th Annual Global Investment Conference Date: | September 14-16, 2026 During the conference, Dr. Cooper will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.  About Lakewood-Amedex Biotherapeutics Inc. Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT ) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin ®  class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com. Contact Investor Relations Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 [email protected]   Media Relations Tiberend Strategic Advisors, Inc. Casey McDonald (646) 577-8520 [email protected]   SOURCE Lakewood-Amedex Biotherapeutics Inc.